Eugenio Morelli

Turin, 10126, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

Journal: Cells
Published: April 02, 2026

A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models.

A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models.

Journal: Blood
Published: January 22, 2026

CRISPR application in hematological disorders: from bench to bedside.

CRISPR application in hematological disorders: from bench to bedside.

Journal: Blood advances
Published: September 10, 2025

DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma.

DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma.

Journal: Blood
Published: June 11, 2025

CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs.

CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs.

Journal: Blood
Published: February 05, 2025

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

Journal: Blood cancer discovery
Published: February 03, 2025

Inhibition of the LINE1-derived MET transcript induces apoptosis and oncoprotein knockdown in cancer cells.

Inhibition of the LINE1-derived MET transcript induces apoptosis and oncoprotein knockdown in cancer cells.

Journal: Molecular therapy. Nucleic acids
Published: August 27, 2024

Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma.

Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma.

Journal: Blood
Published: August 19, 2024

Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma.

Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 17, 2024

Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.

Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 03, 2024

Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 15, 2024

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.

Journal: Blood
Published: October 04, 2023
Showing 1-12 of 48

Last Updated: 09/26/2026